MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

被引:0
作者
Olivier J. Switzeny
Markus Christmann
Mirjam Renovanz
Alf Giese
Clemens Sommer
Bernd Kaina
机构
[1] University Medical Center of the Johannes Gutenberg University Mainz,Department of Toxicology
[2] University Medical Center of the Johannes Gutenberg University Mainz,Department of Neurosurgery
[3] University Medical Center of the Johannes Gutenberg University Mainz,Department of Neuropathology
来源
Clinical Epigenetics | 2016年 / 8卷
关键词
MGMT; Alkyltransferase; Brain tumors; Glioblastoma; Temozolomide; Promoter methylation; Epigenetic silencing; IDH1;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 309 条
[1]  
Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-96
[2]  
Mason WP(2009)Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459-66
[3]  
van den Bent MJ(2007)MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents DNA Repair (Amst) 6 1079-99
[4]  
Weller M(2013)Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma J Clin Oncol 31 3212-8
[5]  
Fisher B(2012)EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma Neuro Oncol 14 1503-10
[6]  
Taphoorn MJ(2012)Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide J Clin Oncol 30 e180-3
[7]  
Belanger K(2002)Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase Carcinogenesis 23 823-30
[8]  
Brandes AA(2002)DNA repair in resistance to alkylating anticancer drugs Int J Clin Pharmacol Ther 40 354-67
[9]  
Marosi C(2008)MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome Int J Cancer 122 1391-9
[10]  
Bogdahn U(2012)Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice Neuro Oncol 14 iv100-8